PolyPid Ltd. (NASDAQ:PYPD) Short Interest Down 15.6% in November

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 13,000 shares, a drop of 15.6% from the October 31st total of 15,400 shares. Based on an average trading volume of 7,000 shares, the short-interest ratio is currently 1.9 days. Approximately 0.4% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of PolyPid in a research note on Wednesday, October 2nd. Craig Hallum started coverage on shares of PolyPid in a research report on Monday, November 4th. They issued a “buy” rating and a $10.00 target price for the company.

PolyPid Trading Down 3.2 %

Shares of PYPD stock opened at $3.34 on Monday. PolyPid has a fifty-two week low of $2.95 and a fifty-two week high of $9.20. The stock’s fifty day moving average price is $3.47 and its two-hundred day moving average price is $3.71. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.00. The company has a market cap of $16.02 million, a PE ratio of -0.43 and a beta of 1.31.

Institutional Trading of PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Stonepine Capital Management LLC bought a new position in PolyPid Ltd. (NASDAQ:PYPD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned about 2.89% of PolyPid at the end of the most recent quarter. Institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.